AKT1 and prostate cancer: Perifosine and MK-2206 are AKT inhibitors with potential anti-tumor effects, as supported by the phase II clinical trials of perifosine in head and neck cancer (50), melanoma (51), breast cancer (52), and colorectal cancer (53), prostate cancer (54) and cervical cancer (55) showing that perifosine has satisfactory therapeutic effects.